A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
Acetates
/ therapeutic use
Administration, Inhalation
Adrenergic beta-2 Receptor Agonists
/ therapeutic use
Adult
Argon
/ therapeutic use
Asthma
/ drug therapy
Bronchodilator Agents
/ therapeutic use
Drug Combinations
Drug Development
Glycopyrrolate
/ therapeutic use
Humans
Indans
Iridium
/ therapeutic use
Mometasone Furoate
/ therapeutic use
Nebulizers and Vaporizers
Pulmonary Disease, Chronic Obstructive
/ drug therapy
Quinolones
Accelerated development strategy
Asthma
Digital companion
Indacaterol acetate/glycopyrronium bromide/mometasone furoate
LABA/LAMA/ICS
Once daily
Single inhaler
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
29
10
2021
accepted:
14
12
2021
pubmed:
25
1
2022
medline:
25
5
2022
entrez:
24
1
2022
Statut:
ppublish
Résumé
A novel, once-daily (o.d.), fixed-dose combination (FDC) of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF), delivered by the inhaler Breezhaler
Identifiants
pubmed: 35072888
doi: 10.1007/s12325-021-02025-w
pii: 10.1007/s12325-021-02025-w
pmc: PMC9122880
doi:
Substances chimiques
Acetates
0
Adrenergic beta-2 Receptor Agonists
0
Bronchodilator Agents
0
Drug Combinations
0
Indans
0
Quinolones
0
Mometasone Furoate
04201GDN4R
Iridium
44448S9773
Argon
67XQY1V3KH
indacaterol
8OR09251MQ
Glycopyrrolate
V92SO9WP2I
Types de publication
Journal Article
Review
Video-Audio Media
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2365-2378Informations de copyright
© 2022. The Author(s).
Références
Enerzair
Atectura
Novartis receives EC approval for Enerzair
EMA’s transformative treatments of 2020. https://www.europeanpharmaceuticalreview.com/article/143977/emas-transformative-treatments-of-2020/ . Accessed 26 Sept 2021.
Katsaounou P, Odemyr M, Spranger O, et al. Still fighting for breath: a patient survey of the challenges and impact of severe asthma. ERJ Open Res. 2018;4:00076–2018.
doi: 10.1183/23120541.00076-2018
Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006;100:1139–51.
doi: 10.1016/j.rmed.2006.03.031
Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.
doi: 10.1038/npjpcrm.2014.9
Global Initiative for Asthma. Global strategy for asthma management and prevention. 2021. http://www.ginasthma.org . Accessed 26 Sept 2021.
Makela MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107:1481–90.
doi: 10.1016/j.rmed.2013.04.005
Murphy KR, Bender BG. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy. 2009;2:63–72.
doi: 10.2147/JAA.S4214
Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45:396–407.
doi: 10.1183/09031936.00075614
Greene G, Costello RW. Personalizing medicine—could the smart inhaler revolutionize treatment for COPD and asthma patients? Expert Opin Drug Deliv. 2019;16:675–7.
doi: 10.1080/17425247.2019.1628017
Johnson N, Varughese B, De La Torre MA, Surani SR, Udeani G. A review of respiratory biologic agents in severe asthma. Cureus. 2019;11:e5690.
pubmed: 31728232
pmcid: 6830845
Barnes PJ, Bonini S, Seeger W, Belvisi MG, Ward B, Holmes A. Barriers to new drug development in respiratory disease. Eur Respir J. 2015;45:1197–207.
doi: 10.1183/09031936.00007915
Onbrez Breezhaler 150 microgram inhalation powder, hard capsules. Summary of product characteristics (SmPC). Last updated 08 Jan 2021. https://www.medicines.org.uk/emc/product/7794/smpc . Accessed 26 Sept 2021.
Zafar MA, Droege C, Foertsch M, Panos RJ. Update on ultra-long-acting beta agonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2014;23(12):1687–701.
doi: 10.1517/13543784.2014.942730
Seebri Breezhaler 44 micrograms inhalation powder, hard capsules. Summary of product characteristics (SmPC). Last updated 09 Jan 2020. https://www.medicines.org.uk/emc/product/2840 . Accessed 26 Sept 2021.
Ultibro Breezhaler 85 micrograms/43 micrograms inhalation powder hard capsules. Summary of product characteristics. Last updated 04 Dec 2020. https://www.medicines.org.uk/emc/product/3496 . Accessed 26 Sept 2021.
Hansel TT, Neighbour H, Erin EM, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest. 2005;128(4):1974–9.
doi: 10.1378/chest.128.4.1974
Pearlman DS, Greos L, LaForce C, Orevillo CJ, Owen R, Higgins M. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol. 2008;101(1):90–5.
doi: 10.1016/S1081-1206(10)60840-X
McCormack PL, Plosker GL. Inhaled mometasone furoate: a review of its use in persistent asthma in adults and adolescents. Drugs. 2006;66(8):1151–68.
doi: 10.2165/00003495-200666080-00011
Tan RA, Corren J. Mometasone furoate in the management of asthma: a review. Ther Clin Risk Manag. 2008;4(6):1201–8.
pubmed: 19337427
pmcid: 2643101
Asmanex Twisthaler 400 micrograms Inhalation Powder. Summary of product characteristics. Last updated 17 Feb 2021. https://www.medicines.org.uk/emc/product/6753/smpc . Accessed 26 Sept 2021.
Clinicaltrials.gov. Efficacy, safety and pharmacokinetics of indacaterol acetate in patients with persistent asthma (CQMF149E2203). Last updated 27 Jan 2015. https://www.clinicaltrials.gov/ct2/show/results/NCT01609478?term=CQMF149E2203&draw=2&rank=1 . Accessed 26 Sept 2021.
Miller D, Vaidya S, Jauernig J, et al. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients. Respir Res. 2020;21(1):248.
doi: 10.1186/s12931-020-01501-1
Seebri Breezhaler. Summary of product characteristics (SmPC). Last updated 09 Jan 2020. https://www.medicines.org.uk/emc/product/2840 . Accessed 26 Sept 2021.
Vaidya S, Ziegler D, Tanase AM, et al. Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers. Pulm Pharmacol Ther. 2021;70:102019.
doi: 10.1016/j.pupt.2021.102019
Buhl R, Nikolaev I, Tillmann HC, et al. Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients with asthma. Pulm Pharmacol Ther. 2021;70:102068.
doi: 10.1016/j.pupt.2021.102068
Buhl R, Tanase AM, Hosoe M, et al. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler
doi: 10.1016/j.pupt.2020.101919
Vaidya SS, Khindri S, Calder N, et al. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects. Pulm Pharmacol Ther. 2016;37:30–6.
doi: 10.1016/j.pupt.2016.01.004
Dal Negro RW. Dry powder inhalers and the right things to remember: a concept review. Multidiscip Respir Med. 2015;10(1):13.
doi: 10.1186/s40248-015-0012-5
Panigone S, Sandri F, Ferri R, Volpato A, Nudo E, Nicolini G. Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment. BMJ Open Respir Res. 2020;7(1):e000571.
doi: 10.1136/bmjresp-2020-000571
Aumônier S, Whiting A, Norris S, Collins M, Coleman T, Fulford B, Breitmayer E. Carbon footprint assessment of Breezhaler® dry powder inhaler. Drug Delivery to the Lungs. Vol. 31. 2020. https://ddl-conference.com/ddl2020-christmas-lectures/conference-papers/carbon-footprint-assessment-ofbreezhaler-dry-powder-inhaler/
Hillman T, Mortimer F, Hopkinson NS. Inhaled drugs and global warming: time to shift to dry powder inhalers. BMJ. 2013;346:f3359.
doi: 10.1136/bmj.f3359
Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, phase IIIb, non-inferiority study (ARGON). Respir Med. 2020;170:106021.
doi: 10.1016/j.rmed.2020.106021
Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000–12.
doi: 10.1016/S2213-2600(20)30190-9
Kornmann O, Mucsi J, Kolosa N, et al. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: phase III randomised QUARTZ study findings. Respir Med. 2020;161:105809.
doi: 10.1016/j.rmed.2019.105809
van Zyl-Smit RN, Krüll M, Gessner C, et al. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. Lancet Respir Med. 2020;8(10):987–99.
doi: 10.1016/S2213-2600(20)30178-8
Scosyrev E, van Zyl-Smit R, Kerstjens H, et al. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials. Respir Med. 2021;180:106311.
doi: 10.1016/j.rmed.2021.106311
European Commission. Union Register of medicinal products for human use—Enerzair Breezhaler. Last updated 27 July 2021. https://ec.europa.eu/health/documents/community-register/html/h1438.htm . Last accessed 24 Sept 2021.
Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options. Press release. https://www.globenewswire.com/en/news-release/2020/06/29/2054449/0/en/Novartis-receives-simultaneous-approval-for-five-new-products-from-Japanese-Ministry-of-Health-Labour-and-Welfare-offering-Japanese-patients-a-broad-range-of-novel-treatment-option.html . Last accessed 24 July 2021.
European Commission. Union Register of medicinal products for human use—Atectura Breezhaler. Last updated 26 Apr 2021. https://ec.europa.eu/health/documents/community-register/html/h1439.htm . Last accessed 24 July 2021.